Free Newsletter
Anticipating sales declines, Allergan cuts 460
Reporting a decline in earnings, Allergan announced that it would lay off 5 percent of its staff, or about 460 workers, primarily in the U.S. and Europe. Hardest hit by the cuts will be sales and marketing staff, the company said, as it adjusts to the "reduced short-term sales outlook" for some of its businesses. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: